AXON vs. VRNA

Last updated Jun 9, 2026

AXON (Axon Enterprise, Inc.) and VRNA (Verona Pharma plc) are both stocks. AXON operates in Aerospace & Defense (Industrials), while VRNA operates in Biotechnology (Healthcare). At a 0.15 correlation, their price movements are largely independent.

Performance

AXON vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Axon Enterprise, Inc. (AXON) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

AXON

• 1D: -3.10%
• 1M: 16.73%
• YTD: -17.06%
• 6M: -14.84%
• 1Y: -40.51%
• 3Y*: 34.22%
• 5Y*: 26.05%
• 10Y*: 35.39%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

AXON vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
AXON Axon Enterprise, Inc.	-17.06%	-4.44%	130.06%	55.69%	5.69%	28.13%	67.21%	67.50%	65.09%	9.23%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%

Correlation

The correlation between AXON and VRNA is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.04
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.18
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.15

The correlation between AXON and VRNA shifts across timeframes, from 0.04 (1 year) to 0.22 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap AXON : $38.85B VRNA : $9.72B
EPS AXON : $2.41 VRNA : -$0.69
PS Ratio AXON : 13.54 VRNA : 57.97
PB Ratio AXON : 10.99 VRNA : 34.92
Total Revenue (TTM) AXON : $2.98B VRNA : $167.65M
Gross Profit (TTM) AXON : $1.77B VRNA : $159.52M
EBITDA (TTM) AXON : $156.24M VRNA : -$40.86M

Return for Risk

AXON vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AXON

AXON Risk / Return Rank: 14
AXON Sharpe Ratio Rank: 11
AXON Sortino Ratio Rank: 13
AXON Omega Ratio Rank: 13
AXON Calmar Ratio Rank: 17
AXON Martin Ratio Rank: 16

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AXON vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Axon Enterprise, Inc. (AXON) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AXON	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.73	—	—
Sortino ratio: Return per unit of downside risk	-0.93	—	—
Omega ratio: Gain probability vs. loss probability	0.88	—	—
Calmar ratio: Return relative to maximum drawdown	-0.67	—	—
Martin ratio: Return relative to average drawdown	-1.17	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	AXON	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.73	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.55	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.72	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.51	—	—

Drawdowns

Drawdown Indicators

	AXON	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-91.78%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-60.28%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-60.28%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-60.28%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-60.28%	—	—
Current Drawdown Current decline from peak	-45.92%	—	—
Average Drawdown Average peak-to-trough decline	-43.59%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	34.81%	—	—

Volatility

Volatility by Period

	AXON	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.02%	—	—
Volatility (6M) Calculated over the trailing 6-month period	44.22%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	55.73%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	47.97%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	49.19%	—	—

Dividends

AXON vs. VRNA - Dividend Comparison

Neither AXON nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

AXON vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Axon Enterprise, Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

AXON - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Axon Enterprise, Inc. reported a gross profit of 477.29M and revenue of 807.35M. Therefore, the gross margin over that period was 59.1%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

AXON - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Axon Enterprise, Inc. reported an operating income of 29.24M and revenue of 807.35M, resulting in an operating margin of 3.6%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

AXON - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Axon Enterprise, Inc. reported a net income of 169.31M and revenue of 807.35M, resulting in a net margin of 21.0%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both AXON and VRNA in my portfolio?

AXON and VRNA have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.